Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Catalent Expands Bioreactor Capacity | Contract Pharma

What are you searching for?

Sign in
Breaking News

Catalent Expands Bioreactor Capacity

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Catalent Pharma Solutions plans to more than double its bioreactor capacity, adding a 1,000-liter bioreactor train at its Middleton, WI facility by 2009. The expansion is in response to increased demand for production to support clinical trials. The company has supplied two biopharma companies with GPEx-produced proteins that are currently being used in FDA-approved IND clinical trials.
   
The GPEx technology is designed to aid in the development of new biopharmaceuticals in a compliant, timely and cost-effective manner. According to the company, the GPEx system produces stable, high-yielding mammalian cell lines for protein production more quickly and efficiently than competing technologies. In addition, GPEx technology has generated more 150 cell lines for production of recombinant proteins and antibodies, one of which is currently being used to manufacture a commercially available biosimilar product.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics